Proteon Therpapeutics Raises $38 Million, Signs Acquisition Option
Proteon Therapeutics, a Waltham, Mass.-based drug developer based in vascular and kidney disease, has raised $38 million in Series B funding. MPM Capital led the round, and was joined by Vectis Healthcare & Life Sciences Fund and return backers TVM Capital, Skyline Ventures, Prism VentureWorks and Intersouth Partners. It had previously raised $12 million. In other Proteon news, the company has signed an acquisition option with Novartis, which is based on regulatory approvals and is valued at around $550 million.
6 March 2009•3 mins read
